Cartesian Therapeutics reports positive Phase IIb results for Descartes-08 in generalized myasthenia gravis, achieving ...

Brexit by the ABPI, emphasizing the need for more resources and flexible licensing. The regulator faces challenges including ...

The battle between the two front runners in the vast weight loss released top-line results from the SURMOUNT-5 Phase IIIb ...

UK’s MHRA is called to restore its reputation post-Brexit by the ABPI, emphasizing the need for more resources and flexible ...

Refoxy Pharmaceuticals secures €9.1 million in seed-extension funding led by Boehringer Ingelheim Venture Fund to advance its ...

Spanish drugmaker PharmaMar Group revealed that its licensing partner, Luye Pharma Group, has received conditional marketing ...

Japanese drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration agreement with privately-held Canadian ...

Maze Therapeutics secures $115 million in Series D funding to advance treatments for kidney and metabolic diseases with ...

Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic ...

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Anzupgo ...

Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutic to further develop, ...

Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in ...